Apogee Therapeutics, Inc.
NASDAQApogee Therapeutics enters its June 9 Q1 readout with the Street tilting constructive and short sellers trimming positions for the third consecutive month — an unusual alignment for a pre-revenue biotech trading at 16% short interest. The options picture is the standout shift this week. The put/call ratio has climbed to 0.82, well above its 20-day average of 0.47 — a jump of…
Snapshot as of 27 May 2026
Apogee Therapeutics enters its June 9 Q1 readout with the Street tilting constructive and short sellers trimming positions for the third consecutive month — an unusual alignment for a pre-revenue biotech trading at 16%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for APGE — free to start on ORTEX.
Sign up for free →Open APGE on ORTEX